Ironwood Pharmaceuticals, Inc. (IRWD)

US — Healthcare Sector
Peers: NBIX  AMPH  COLL  ANIP  ALKS  ITCI  DCPH  PCRX  AVDL  EGRX  ASRT  ESPR 

Automate Your Wheel Strategy on IRWD

With Tiblio's Option Bot, you can configure your own wheel strategy including IRWD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IRWD
  • Rev/Share 1.9735
  • Book/Share -2.0752
  • PB -0.2988
  • Debt/Equity -1.7934
  • CurrentRatio 3.3386
  • ROIC -0.2602

 

  • MktCap 100328400.0
  • FreeCF/Share 0.4871
  • PFCF 1.2795
  • PE -3.1774
  • Debt/Assets 1.8309
  • DivYield 0
  • ROE 0.0991

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade IRWD Jefferies Buy Hold -- -- April 15, 2025
Downgrade IRWD Wells Fargo Overweight Equal Weight -- -- April 15, 2025
Downgrade IRWD Citizens JMP Mkt Outperform Market Perform -- -- April 14, 2025
Initiation IRWD Leerink Partners -- Market Perform -- $5 Sept. 9, 2024

News

Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
IRWD
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Negative

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
IRWD
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Negative

Ironwood incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year.

Read More
image for news IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
IRWD
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Ironwood Pharmaceuticals (IRWD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.02 per share a year ago.

Read More
image for news Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
IRWD
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its first quarter 2025 results and recent business performance. “LINZESS demand continues to be strong, and we remain on track to meet our full-year 2025 guidance and further, recently raised our adjusted EBITDA guidance. We are making a concerted effort to maximize st.

Read More
image for news Ironwood Pharmaceuticals Reports First Quarter 2025 Results
Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
IRWD
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative

Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Analysts Estimate Ironwood Pharmaceuticals (IRWD) to Report a Decline in Earnings: What to Look Out for
Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
IRWD
Published: April 14, 2025 by: Benzinga
Sentiment: Negative

Ironwood Pharmaceuticals, Inc. IRWD on Monday announced that the U.S. Food and Drug Administration (FDA) wants a confirmatory Phase 3 trial to approve apraglutide for short bowel syndrome with intestinal failure.

Read More
image for news Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal Drug
Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
IRWD
Published: April 10, 2025 by: Seeking Alpha
Sentiment: Positive

Ironwood Pharmaceuticals (IRWD) is undergoing a challenging transition with LINZESS but has promising growth potential with apraglutide for short bowel syndrome (SBS). Despite declining revenue, LINZESS remains the market leader, and Ironwood's restructuring efforts aim to streamline operations and focus on apraglutide. Apraglutide's strong clinical data and potential FDA approval could significantly boost Ironwood's revenue, positioning it as a key player in the SBS market.

Read More
image for news Ironwood Pharmaceuticals: Setting A Strong Foundation For A Return To Growth
Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund
IRWD
Published: March 25, 2025 by: Business Wire
Sentiment: Neutral

SAN ANTONIO--(BUSINESS WIRE)--Ironwood Midstream Energy Partners III, LLC (Ironwood III) today announced it has secured a substantial equity commitment from Kayne Anderson Energy Infrastructure Fund, Inc. (KYN). Led by industry veteran Mike Williams, Ironwood III has a long-term operating strategy, focused on the acquisition, development, and operation of top-tier midstream assets in the most economic and desirable oil and gas producing regions in the United States. In conjunction with the equi.

Read More
image for news Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund
Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
INVA, IRWD, NBIX
Published: March 17, 2025 by: 24/7 Wall Street
Sentiment: Neutral

If you work in the biotech industry, you might know the name Alex Denner.

Read More
image for news Billionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 Stocks
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
IRWD
Published: February 28, 2025 by: Zacks Investment Research
Sentiment: Negative

Ironwood reports weaker-than-expected results for the fourth quarter of 2024. The company maintains total revenue guidance for 2025.

Read More
image for news IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down

About Ironwood Pharmaceuticals, Inc. (IRWD)

  • IPO Date 2010-02-03
  • Website https://www.ironwoodpharma.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Thomas A. McCourt
  • Employees 253

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.